Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) have been assigned a consensus rating of “Moderate Buy” from the four ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $4.33.

ONCY has been the subject of several recent analyst reports. Maxim Group lowered their target price on shares of Oncolytics Biotech from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Monday, March 10th. Royal Bank of Canada lowered their target price on shares of Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating for the company in a research note on Monday, March 10th. Jones Trading reaffirmed a “hold” rating on shares of Oncolytics Biotech in a research note on Friday, May 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Oncolytics Biotech in a research note on Wednesday, May 21st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ONCY. Virtu Financial LLC acquired a new position in shares of Oncolytics Biotech in the fourth quarter valued at approximately $90,000. National Bank of Canada FI raised its position in Oncolytics Biotech by 199.6% in the 4th quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock valued at $60,000 after buying an additional 42,955 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Oncolytics Biotech by 59.6% in the 4th quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock valued at $61,000 after buying an additional 24,997 shares during the last quarter. Institutional investors and hedge funds own 6.82% of the company’s stock.

Oncolytics Biotech Price Performance

ONCY opened at $0.44 on Tuesday. The company has a market cap of $38.51 million, a price-to-earnings ratio of -1.65 and a beta of 0.71. The firm has a 50 day simple moving average of $0.49 and a 200 day simple moving average of $0.68. Oncolytics Biotech has a fifty-two week low of $0.33 and a fifty-two week high of $1.53.

Oncolytics Biotech (NASDAQ:ONCY) last issued its earnings results on Wednesday, May 14th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.03. As a group, analysts expect that Oncolytics Biotech will post -0.28 EPS for the current year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.